Acrodermatitis continua of Hallopeau in a patient with myelodysplastic syndrome

P C van der Kerkhof1, P M Steijlen, R A Raymakers

  • 1Department of Dermatology, University Hospital, Nijmegan, Netherlands.

Insights

Acrodermatitis continua of Hallopeau (ACH) is a rare psoriasis manifestation. Acitretin effectively treated ACH but transformed myelodysplastic syndrome (MDS) into acute myeloid leukemia, necessitating caution with retinoids in MDS patients.

Area of Science:

  • Dermatology
  • Hematology
  • Oncology

Background:

  • Acrodermatitis continua of Hallopeau (ACH) is a rare, debilitating pustular psoriasis variant.
  • Myelodysplastic syndrome (MDS) is a group of clonal hematopoietic stem cell disorders.

Observation:

  • This case report details a patient with ACH and MDS treated with acitretin.
  • Acitretin demonstrated efficacy in managing ACH symptoms.
  • The patient developed acute myeloid leukemia (AML) during acitretin therapy.

Findings:

  • Retinoids, including acitretin, can impact bone marrow function in normal subjects, MDS patients, and AML patients.
  • The transformation of MDS to AML occurred during acitretin treatment.
  • Available literature and this case suggest caution when using aromatic retinoids in MDS patients.

Implications:

  • Aromatic retinoids like acitretin and etretinate are not recommended for patients with MDS.
  • If retinoid treatment is necessary for MDS patients, intensive hematological monitoring is crucial.
  • This highlights the potential risks of retinoids in patients with pre-existing bone marrow disorders.